[A12-18] Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 15.03.2013
Commission awarded on 14.12.2012 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-53||Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-37||Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A13-18||Addendum to Commission A12-18 (dapagliflozin)||Commission completed|